Astrazeneca (AZN) Change in Cash (2009 - 2026)

Astrazeneca (AZN) has reported Change in Cash for 16 consecutive years, with $5.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 4.95% year-over-year to $5.7 billion; the TTM figure through Mar 2026 stood at $492.0 million (up 252.32% YoY), while the FY2025 annual figure was $223.0 million, up 293.91% from the prior year.
• Change in Cash came in at $5.7 billion for Q1 2026 at Astrazeneca, up from -$5.2 billion in the prior quarter.
• The five-year high for Change in Cash was $6.1 billion in Q2 2023, with the low at -$5.8 billion in Q4 2024.
• Average Change in Cash over 5 years is $1.1 billion, with a median of -$144.0 million recorded in 2023.
• Across the five-year window, Change in Cash slumped 253.55% in 2022 and soared 4014.58% in 2024, its largest moves.
• Year by year, Change in Cash stood at -$847.0 million in 2022, then surged by 823.38% to $6.1 billion in 2023, then sank by 193.88% to -$5.8 billion in 2024, then increased by 9.49% to -$5.2 billion in 2025, then jumped by 209.45% to $5.7 billion in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $5.7 billion, -$5.2 billion, and $5.4 billion for Q1 2026, Q4 2025, and Q1 2025 respectively.